B+
Bull case
25%
Probability
Target price
$21.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
NEO
NeoGenomicsCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$18.50
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$13.25
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-31
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+64.6
Score
AI commentary
The primary earnings release materially improved the operating narrative, but the packet does not provide verified post-print analyst revisions, target changes, or a clean multi-day market-reaction series. Social coverage is unavailable. Sentiment is therefore positive but best treated as medium-confidence monitoring rather than a fully confirmed rerating thesis.
RankAlpha Sentiment Codex - 2026-07-31
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-28eventQ2 earnings showed durable growth and raised FY2026 guidanceHigh impact
Second-quarter revenue rose 11% year over year to $202 million, clinical services grew 14%, NGS grew 26%, and adjusted EBITDA increased 36%. Management also raised full-year 2026 revenue and adjusted EBITDA guidance. [#SEC-8K-2026-07-28] [#8-K-2026-07-28]
2026-08-31catalystRaised guidance becomes the next execution benchmarkMedium impact
The post-earnings setup now depends on converting the raised full-year outlook into sustained revenue growth and margin expansion. The packet does not show delayed analyst estimate or target revisions, so this remains a monitoring catalyst rather than a confirmed rerating signal.
2026-12-31catalystAdvanced oncology testing and reimbursement expansionHigh impact
Growth is shifting toward advanced testing, while the company continues commercial execution around oncology and has submitted additional RaDaR ST evidence to MolDx. The third submission remains pending approval, leaving meaningful execution and reimbursement optionality but limited near-term certainty. [#SEC-8K-2026-07-28] [#SEC-8K-2026-04-28]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-31 • Updated nightlySource: Internal modelMethodology